OncoMatch/Clinical Trials/NCT06819215

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Is NCT06819215 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies VB15010 for cancer.

Phase 1/2RecruitingZhejiang Yangli Pharmaceutical Technology Co., Ltd.NCT06819215Data as of May 2026

Treatment: VB15010 — This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Ovarian Cancer

Prostate Cancer

Pancreatic Cancer

Cholangiocarcinoma

Colorectal Cancer

Prior therapy

Cannot have received: major surgery

Major surgery within 4 weeks of the first dose of study treatment.

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify